# A Study to Evaluate the Safety and Efficacy of Fycompa® (Perampanel) as Add-on Therapy in Participants With Epilepsy

> **NCT04230044** · — · COMPLETED · sponsor: **Eisai Co., Ltd.** · enrollment: 117 (actual)

## Conditions studied

- Epilepsy
- Partial-onset Seizures

## Interventions

- **DRUG:** Perampanel

## Key facts

- **NCT ID:** NCT04230044
- **Lead sponsor:** Eisai Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-11
- **Primary completion:** 2017-07-03
- **Final completion:** 2017-07-03
- **Target enrollment:** 117 (ACTUAL)
- **Last updated:** 2020-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04230044

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04230044, "A Study to Evaluate the Safety and Efficacy of Fycompa® (Perampanel) as Add-on Therapy in Participants With Epilepsy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04230044. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*